TY  - JOUR
AU  - Karschnia, Philipp
AU  - Young, Jacob S
AU  - Wijnenga, Maarten M J
AU  - Sciortino, Tommaso
AU  - Teske, Nico
AU  - Corell, Alba
AU  - Wagner, Arthur
AU  - Youssef, Gilbert
AU  - Park, Yae Won
AU  - Häni, Levin
AU  - Jünger, Stephanie T
AU  - Dono, Antonio
AU  - Ehret, Felix
AU  - Mireles, Eduardo E Mendoza
AU  - Neidert, Nicolas
AU  - Bruno, Francesco
AU  - Tuchek, Chad A
AU  - van der Vaart, Thijs
AU  - Rossi, Marco
AU  - Nibali, Marco Conti
AU  - Gay, Lorenzo
AU  - Gramelt, Alfred
AU  - Tandon, Nitin
AU  - Ahn, Sung Soo
AU  - Chang, Jong Hee
AU  - Weller, Michael
AU  - Vincent, Arnaud J P E
AU  - Goldbrunner, Roland
AU  - Cahill, Daniel P
AU  - Huang, Raymond Y
AU  - Raabe, Andreas
AU  - Meyer, Bernhard
AU  - Beck, Juergen
AU  - Molinaro, Annette M
AU  - Chang, Susan M
AU  - Vogelbaum, Michael A
AU  - Rudà, Roberta
AU  - Vik-Mo, Einar O
AU  - Dietrich, Jorg
AU  - Esquenazi, Yoshua
AU  - Grau, Stefan J
AU  - Wen, Patrick Y
AU  - Jakola, Asgeir S
AU  - Schnell, Oliver
AU  - Bello, Lorenzo
AU  - van den Bent, Martin J
AU  - Hervey-Jumper, Shawn
AU  - Berger, Mitchel S
AU  - Tonn, Joerg-Christian
TI  - A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group.
JO  - The lancet / Oncology
VL  - 26
IS  - 12
SN  - 1470-2045
CY  - London
PB  - The Lancet Publ. Group
M1  - DKFZ-2025-02642
SP  - 1638 - 1650
PY  - 2025
AB  - The efficacy of resection in IDH-mutant grade 2 gliomas remain controversial since terminology for the extent of resection has been inconsistently applied across studies. We aimed to establish a standardised classification for the extent of resection and assess the association between supramaximal resection and survival across molecular subtypes.In this international, multicentre, retrospective study, patients aged 18 years and older with newly diagnosed grade 2 IDH-mutant glioma were identified from institutional databases across 16 centres in the USA, Europe, and Asia between between Sept 1, 1993, and May 10, 2024. We used Cox proportional hazard regressions to analyse the associations between residual tumour and progression-free survival and overall survival. Patients were stratified according to a previously postulated classification system based on residual tumour volume. A cohort of patients from UCSF diagnosed between Feb 16, 1998, and Nov 14, 2017, was used for geographically and institutionally independent external validation.We identified 1391 patients with newly diagnosed IDH-mutant grade 2 gliomas, with a median follow-up of 81 months (95
KW  - Humans
KW  - Middle Aged
KW  - Female
KW  - Isocitrate Dehydrogenase: genetics
KW  - Male
KW  - Retrospective Studies
KW  - Adult
KW  - Brain Neoplasms: surgery
KW  - Brain Neoplasms: genetics
KW  - Brain Neoplasms: pathology
KW  - Brain Neoplasms: mortality
KW  - Brain Neoplasms: classification
KW  - Mutation
KW  - Glioma: surgery
KW  - Glioma: genetics
KW  - Glioma: pathology
KW  - Glioma: mortality
KW  - Prognosis
KW  - Neoplasm Grading
KW  - Aged
KW  - Progression-Free Survival
KW  - Young Adult
KW  - Neurosurgical Procedures: mortality
KW  - Neoplasm, Residual
KW  - Isocitrate Dehydrogenase (NLM Chemicals)
KW  - IDH2 protein, human (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41308678
DO  - DOI:10.1016/S1470-2045(25)00534-0
UR  - https://inrepo02.dkfz.de/record/306605
ER  -